Lu Kun-Hui, Tounsi Amel, Shridhar Naveen, Küblbeck Günter, Klevenz Alexandra, Prokosch Sandra, Bald Tobias, Tüting Thomas, Arnold Bernd
Department of Molecular Immunology, German Cancer Research Center (DKFZ) , Heidelberg , Germany.
Laboratory of Experimental Dermatology, Department of Dermatology and Allergy, University of Bonn , Bonn , Germany.
Front Immunol. 2015 Dec 24;6:645. doi: 10.3389/fimmu.2015.00645. eCollection 2015.
Mesenchymal stem cells (MSCs) are known to limit immune responses in vivo by multiple soluble factors. Dickkopf-3 (DKK3), a secreted glycoprotein, has recently been identified as a novel immune modulator. Since DKK3 has been reported to be produced by MSCs, we investigated whether DKK3 contributes to the immune suppression of anti-tumor responses by MSCs. Whereas wild-type MSCs inhibited immune responses against two different transplantation tumors, DKK3-deficient MSCs did not affect the rejection process. Increased CD8(+) T cell and reduced M2-type macrophages infiltration was observed in tumors inoculated together with DKK3-deficient MSCs. Thus, DKK3 could alter the composition of the tumor stroma, thereby supporting the MSCs-mediated suppression of immune responses against these tumor transplants.
间充质干细胞(MSCs)已知可通过多种可溶性因子在体内限制免疫反应。Dickkopf-3(DKK3)是一种分泌型糖蛋白,最近被鉴定为一种新型免疫调节剂。由于据报道DKK3由MSCs产生,我们研究了DKK3是否有助于MSCs对抗肿瘤反应的免疫抑制作用。野生型MSCs可抑制针对两种不同移植肿瘤的免疫反应,而DKK3缺陷型MSCs则不影响排斥过程。在与DKK3缺陷型MSCs一起接种的肿瘤中,观察到CD8(+) T细胞浸润增加,M2型巨噬细胞浸润减少。因此,DKK3可改变肿瘤基质的组成,从而支持MSCs介导的对这些肿瘤移植的免疫反应抑制。